Save Product
Product Details
Source
Monoclonal Anti-RSV-Pre-F0 specific Antibody, Mouse IgG1 (12C6) (Cat. No. RS0-Y132) is a mouse monoclonal antibody produced from a hybridoma generated by fusion of SP2/0 myeloma cells with mouse B lymphocytes.
Antibody Type
Hybridoma Monoclonal
Clone
12C6
Isotype
Mouse IgG1, Kappa
Host Species
Mouse
Reactivity
Virus
Immunogen
Recombinant HRSV (A) Fusion glycoprotein F0 derived from human 293 cells
Specificity
This product is a specific antibody specifically reacts with Prefusion glycoprotein F0/pre-F protein (RSV).
Application
ApplicationRecommended Use / PerformanceELISA0.2-2 μg/mLPurification
Protein A purified.
Aggregation
Less than 5%, as determined by SEC-MALS.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70 °C for 3 months after reconstitution;
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (MALS verified) (Cat. No. RSF-V52H7) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-RSV-Pre-F0 specific Antibody, Mouse IgG1 (12C6) (Cat. No. RS0-Y132) with a linear range of 0.098-3.125 ng/mL (QC tested). The antibody does not bind HRSV (A) Post-fusion glycoprotein F0, His Tag (MALS verified) (Cat. No. RSF-V52H6) (Routinely tested).
Protocol
Immobilized HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-RSV-Pre-F0 specific Antibody, Mouse IgG1 (12C6) (Cat. No. RS0-Y132) with a linear range of 0.5-8 ng/mL. HRSV (B) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H9) is verified not recoginized by Monoclonal Anti-RSV-Pre-F0 specific Antibody, Mouse IgG1 (12C6) (Cat. No. RS0-Y132) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
- Product
What do “pre” and “post” refer to in the names of viral proteins?
In virology, “pre” refers to the conformation of a viral surface glycoprotein before fusion with the host cell membrane, while “post” refers to the conformation after membrane fusion and entry into the host cell. Both are naturally occurring states in the viral life cycle. Because the “pre” conformation represents a critical stage before viral entry, antibodies designed against this state often exhibit stronger neutralizing activity and are therefore more effective in preventing infection.
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
